The most commonly reported side effects of raxibacumab include cholecystitis, exposure during pregnancy, and off label use, based on 4 FDA adverse event reports from 2014 to 2023.
Percentages show how often each reaction appears relative to total reports for raxibacumab.
These are voluntary reports and do not establish that raxibacumab caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside raxibacumab. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
50.0% of raxibacumab adverse event reports involve female patients and 50.0% involve male patients. The largest age group is adult at 100%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking raxibacumab when the adverse event was reported.
Raxibacumab is sold under the brand name Raxibacumab.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.